BFS
PTGX icon

Bare Financial Services’s Protagonist Therapeutics PTGX Stock Holding History

Bare Financial Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10K Sell
95
-15
-14% -$1.33K ﹤0.01% 344
2025
Q4 		$9.61K Buy
110
+76
+224% +$6.22K ﹤0.01% 260
2025
Q3 		$2.26K Buy
34
+11
+48% +$625 ﹤0.01% 783
2025
Q2 		$1.27K Buy
+23
New +$1.1K ﹤0.01% 843

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Bare Financial Services's PTGX Position: Q1 2026 in Review

Bare Financial Services reduced its Protagonist Therapeutics (PTGX) stake by 14% in Q1 2026, selling an estimated $1.33K and leaving 95 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #344.

Bare Financial Services first reported a position in PTGX in Q2 2025 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Bare Financial Services held 95 shares of Protagonist Therapeutics worth $10K as of Q1 2026.
  • Bare Financial Services sold 15 Protagonist Therapeutics shares in Q1 2026, an estimated $1.33K.
  • Protagonist Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #344 holding.
  • Bare Financial Services first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.